WANY
GMAB icon

Wealthspire Advisors (New York)’s Genmab GMAB Stock Holding History

Wealthspire Advisors (New York)’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-32,205
Closed -$682K – 372
2020
Q1 		$682K Buy
+32,205
New +$718K 0.03% 253

Other funds holding GMAB

Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Wealthspire Advisors (New York)'s GMAB Position: Q2 2020 in Review

Wealthspire Advisors (New York) sold out of Genmab (GMAB) in Q2 2020, closing a stake of 32,205 shares — an estimated $682K sold.

Wealthspire Advisors (New York) first reported a position in GMAB in Q1 2020 and held it in 1 quarter. The position peaked at $682K in Q1 2020. 174 funds tracked by Wall St. Rank hold GMAB as of Q2 2020.

  • Wealthspire Advisors (New York) reported no remaining Genmab position as of Q2 2020 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 32,205 Genmab shares in Q2 2020, an estimated $682K.
  • Wealthspire Advisors (New York) first reported a position in Genmab in Q1 2020 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s Genmab position peaked at $682K in Q1 2020.
  • 174 funds tracked by Wall St. Rank held Genmab as of Q2 2020.

Based on Wealthspire Advisors (New York)'s 13F filing for Q2 2020, filed 14 Aug 2020.